Are Analyst Price Targets Accurate? 7 Years of Data
How often Wall Street price targets are reached, how long it takes, and how the promised upside compares with what stocks actually did. From Exent’s backtest of 628,792 analyst ratings.
How often Chase Knickerbocker’s price targets were reached, how fast, and what the stocks did after each call: a 7‑year backtest of 1,080 ratings, compared with the average Wall Street analyst.
Chase Knickerbocker of Craig-Hallum ranks #112 of the 1,000 analysts Exent scores, with a 5.0★ rating and a focus on healthcare. Over a 7‑year lookback, 35.8% of Chase’s price targets were reached, 16.6 points below the 52.4% average across all analysts.
| Metric | Chase Knickerbocker | All analysts |
|---|---|---|
| Price‑target hit rate | 35.8% | 52.4% |
| Median days to hit target | 117 days | 91 days |
| Calls up after 12 months | 57.5% | 64.0% |
| Median 12‑month return of calls | +11.2% | +13.4% |
| Hit rate, last 2 years | 34.6% | — |
| Average worst drop after a call | −27.7% | — |
| Ratings in the sample | 1,080 | — |
| Stocks covered | 43 | — |
| Time to reach the target | Chase Knickerbocker |
|---|---|
| Under 30 days | 8.0% |
| 30–90 days | 32.0% |
| 90–180 days | 32.0% |
| Over 180 days | 28.0% |
Share of the targets that were reached, by how long they took. Targets are usually set for 12 months.
| Stock | Ratings in the sample |
|---|---|
| BFLY | 28 |
| ETON | 28 |
| MDXG | 27 |
| HROW | 27 |
| CVRX | 25 |
| XERS | 23 |
| DCTH | 19 |
| BVS | 19 |
In the past year Chase’s ratings were 99% Buy, 1% Hold and 0% Sell.
| Date | Stock | Action | Rating | Price target |
|---|---|---|---|---|
| Sep 17, 2026 | INDV | Reiterated: Buy | Buy | $0.00 |
| Sep 17, 2026 | NRXS | Rated: Buy | Buy | $13.00 |
| Sep 10, 2026 | XERS | Rated: Buy | Buy | $12.00 |
| Sep 8, 2026 | MDXG | Reiterated: Buy | Buy | $8.00 |
| Sep 2, 2026 | GUTS | Reiterated: Buy | Buy | $4.00 |
| Sep 2, 2026 | BFLY | Reiterated: Buy | Buy | $10.00 |
| Aug 18, 2026 | BFLY | Reiterated: Buy | Buy | $10.00 |
| Aug 18, 2026 | CELC | Reiterated: Buy | Buy | $173.00 |
| Aug 18, 2026 | GRCE | Reiterated: Buy | Buy | $4.00 |
| Aug 14, 2026 | ETON | Reiterated: Buy | Buy | $76.00 |
| Aug 14, 2026 | ACOG | Reiterated: Buy | Buy | $17.00 |
| Aug 12, 2026 | FENC | Rated: Buy | Buy | $18.00 |
Live ratings from Chase Knickerbocker and the other top‑ranked analysts, and the stocks where they agree, are in Exent Stocks Radar.
Exent replays every rating with a price target over a 7‑year lookback: was the target reached, how long it took, and what the stock returned 1, 3, 6 and 12 months after the call. The star rating and rank combine success rate, average return and the number of ratings, so a few lucky calls do not make a top analyst. Statistics as of Jun 24, 2026; ranking updated Oct 19, 2026. How accurate are analyst price targets overall?
Past performance does not guarantee future results. Historical figures are calculated by Exent from market data and are for education only; they are not investment advice or a recommendation to buy or sell any security.
By Exent’s scoring Chase Knickerbocker ranks #112 of 1,000 with a 5.0★ rating. 35.8% of price targets were reached over a 7-year lookback (all analysts: 52.4%), and 57.5% of calls were up 12 months later. Past accuracy does not guarantee future accuracy.
Chase Knickerbocker’s success rate is 55.6% by the ranking source and 35.8% by Exent’s price-target hit-rate backtest, with a median of 117 days to reach a target.
Chase Knickerbocker (Craig-Hallum) covers 43 stocks, mostly in healthcare. The most frequently rated are BFLY, ETON, MDXG, HROW, CVRX.
Exent tracks 4,000+ analysts, keeps only the elite few with proven records, and surfaces the Gems where they agree.
Educational content, not investment advice. Examples are illustrative; past performance does not guarantee future results.